Analisis Efektivitas Biaya Penggunaan Obat Antihipertensi pada Pasien Stroke Iskemik di Rumah Sakit Pendidikan Prof. dr. Chairuddin Panusunan Lubis Medan

Abstract

Background: Stroke is one of the leading causes of death and neurological disability. Stroke has a negative impact on the quality of life, social and economic development of patients and their families. Pharmacoeconomic analysis is necessary to determine the economic impact of a treatment therapy. The cost effectiveness analysis method is used to determine and select effective health programs among various treatment options. Objective: To determine the antihypertensive therapy model used by ischemic stroke patients and the most cost-effective antihypertensive therapy model at Prof. dr. Chairuddin Panusunan Lubis educational hospital Medan. Method: This study is non-experimental and uses a retrospective cohort study design. Data were obtained from the medical records of ischemic stroke patients who were hospitalized at the Prof. dr. Chairuddin Panusunan Lubis Educational Hospital during the period of January 2023-December 2023. Results: 38 patients who met the inclusion criteria were obtained. Most of them were female (55%) and aged ≥55 years (66%). The research results show that the combination of amlodipine + ramipril is an antihypertensive therapy model with the lowest Cost Effective Ratio (CER) and Incremental Cost Effective Ratio (ICER), which are Rp 1,651 and Rp -46,333, respectively. Conclusion: There are 5 antihypertensive therapy models used by ischemic stroke patients, namely the combination of amlodipine + ramipril, amlodipine, amlodipine + candesartan, amlodipine + bisoprolol + candesartan, and amlodipine + candesartan + furosemide injection. The most cost-effective antihypertensive therapy model is amlodipine + ramipril.